Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T-cell candidates in solid tumors and hematological malignancies.
Celyad Oncology’s headquarters are located in Mont-Saint-Guibert, Belgium.
Celyad Oncology is committed to delivering innovative immunotherapies to patients with advanced cancer seeking novel treatment options
Mission & Vision
Developing innovative cell therapies against cancer
At Celyad Oncology, we are driven by the promise of delivering relevant treatment options to patients. Our goal is to discover, develop and contribute meaningfully to new therapies that will irradicate cancer. We believe that our innovative CAR T-cell candidates could offer patients with advanced disease alternative therapeutic options where no other treatments exist. Delivering best-in-class cell therapies for patients with unmet medical needs is our top priority.
At Celyad Oncology, our goal is to eliminate cancer and improve life.